The Cologuard Plus test is being offered as an in-network service to eligible Humana Medicare Advantage members.

Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A ...

Exact Sciences (EXAS) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results ...

The Oncodetect test is a highly sensitive, tumor-informed assay that empowers oncologists and patients with critical insights ...

In fact, eight times out of ten, EXAS stock has popped higher in the week following the flashing of the 2-8-D sequence, with a median return of 4.91%. It’s possible, then, that within a week or two, ...

University research in Wisconsin led to $500 million Third Wave business, screening tests for cancer, including Cologuard ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that its Oncodetect™ molecular residual dis ...

Detailed price information for Exact Sciences Cor (EXAS-Q) from The Globe and Mail including charting and trades.

With rates of colorectal cancer (CRC) surging among younger populations, Guardant Health is turning to a famous face beloved ...